Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization

February 15, 2020
Alberto Santagostino

Alberto Santagostino is senior vice-president and head of cell and gene technologies at Lonza Pharma and Biotech.

BioPharm International, BioPharm International-02-15-2020, Volume 2020 eBook, Issue 1
Pages: 12-15

Contract partners must help innovator biotechs consider manufacturability as early as possible in development. This requires focusing on technical and operational performance, as well as cost.

The cell and gene therapy industry is at a major inflection point, as therapies move out of clinical trials and into the commercial market. As more therapies are commercialized and become established, demand for cell and gene therapies will grow, leading to vast changes in patient care.

Read this article in BioPharm International’s Outsourcing Resources February 2020 eBook. 

Article Details

BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Pages: 12–15

Citation

When referring to this article, please cite it as A. Santagostino, “Using the “Cubic Effect” to Drive Cell and Gene Therapy Commercialization," BioPharm International Outsourcing Resources eBook (February 2020).